The Clinical And Experimental Study Of En-Riching, Stanch-Bleeding And Eye-Brighting Tablet For Diabetic Retinopathy

OBJECTIVE: To evaluate the effects of En-Riching ,Stanch-Bleeding and Eye-Brighting Tablet (ESET) in NIDDM patients with non-proliferative diabetic retinopathy (NPDR).Methods: 60 NIDDM patients with NPDR were randomly assigned (30 : 30) to the treatment group (ESET) and the controlled group (Capsules of Calcium Dobesilate, CCD). Ophthalmic examination , visual acuity testing , visual field testing , color photographs , fundus fluorescein angiograms and a series of physical , biochemical tests were used to evaluate the effects of ESET and CCD at 4th week and 8th week , respectively.Results: 57 patients (29:28)completed the whole trial. The final outcome showed the total effective rates was 86.2% ,82.1%(P>0.05); In both groups the area of intraretinal exudation , hemorrhage, retinal non-perfusion and and fluorescein leakage were smaller and intragroup changes were significantly different ( P<0.05 ). The best corrected visual acuity was improved at 8th week ( P<0.05 ).And all the changes were not significant between the groups ( P>0.05 ); No significant changes were observed as to the visual field loss , between or intragroup . The content of HbAlc , ET and VEGF was decreased and that of CGRP was increased in the two groups .A series of experiments showed that the SanQiZhongDai(SQZD) can decrease the expression of VEGF mRNA and MMPs of AGEs treated RPEs.CONCLUSIONS: ESET can improve the conditions of the NIDDM patients with NPDR and thus is effective for the treatment of them.